文献速递神经免疫

多发性硬化高效治疗时机:回顾性观察队列研究

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
PubMed 文献 · Lancet Neurol · 2020-03-18

该回顾性国际观察研究基于MSBase和瑞典MS注册库,比较发病2年内(早期)与4-6年后(晚期)启动高效治疗的多发性硬化患者长期残疾结局。匹配后分析显示,早期组在发病6-10年时的EDSS评分显著低于晚期组,差异持续存在且具统计学意义。结论提示发病2年内启动高效治疗与更少长期残疾相关。

要点

  • 发病2年内启动高效治疗与6-10年后更少残疾相关。

核心结论

  • 发病2年内启动高效治疗与6-10年后更少残疾相关,可辅助治疗时机决策。

研究设计与样本

  • 回顾性国际观察研究,数据来自MSBase和瑞典MS注册库。
  • 纳入≥18岁复发缓解型多发性硬化患者,随访至少6年,高效治疗为利妥昔单抗、奥瑞利珠单抗、米托蒽醌、阿仑单抗或那他珠单抗。
  • 早期组为发病0-2年启动,晚期组为4-6年启动,采用倾向评分匹配。

临床怎么用

  • 对复发缓解型多发性硬化患者,可考虑在发病2年内启动高效治疗以改善长期残疾结局。

局限性

  • 回顾性观察设计,可能存在残余混杂。
  • 仅纳入两个注册库数据,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset with those who started 4-6 years after disease onset. METHODS: In this retrospective international observational study, we obtained data from the MSBase registry and the Swedish MS registry, which prospectively collect patient data that are specific to multiple sclerosis as part of routine clinical care. We identified adult patients (aged ≥18 years) with relapsing-remitting multiple sclerosis, with at least 6 years of follow-up since disease onset, and who started the high-efficacy therapy (rituximab, ocrelizumab, mitoxantrone, alemtuzumab, or natalizumab) either 0-2 years (early) or 4-6 years (late) after clinical disease onset. We matched patients in the early and late groups using propensity scores calculated on the basis of their baseline clinical and demographic data. The primary outcome was disability, measured with the Expanded Disability Status Score (EDSS; an ordinal scale of 0-10, with higher scores indicating increased disability), at 6-10 years after disease onset, assessed with a linear mixed-effects model. FINDINGS: We identified 6149 patients in the MSBase registry who had been given high-efficacy therapy, with data collected between Jan 1, 1975, and April 13, 2017, and 2626 patients in the Swedish MS Registry, with data collected between Dec 10, 1997, and Sept 16, 2019. Of whom, 308 in the MSBase registry and 236 in the Swedish MS registry were eligible for inclusion. 277 (51%) of 544 patients commenced therapy early and 267 (49%) commenced therapy late. For the primary analysis, we matched 213 patients in the early treatment group with 253 in the late treatment group. At baseline, the mean EDSS score was 2·2 (SD 1·2) in the early group and 2·1 (SD 1·2) in the late group. Median follow-up time for matched patients was 7·8 years (IQR 6·7-8·9). In the sixth year after disease onset, the mean EDSS score was 2·2 (SD 1·6) in the early group compared with 2·9 (SD 1·8) in the late group (p<0·0001). This difference persisted throughout each year of follow-up until the tenth year after disease onset (mean EDSS score 2·3 [SD 1·8] vs 3·5 [SD 2·1]; p<0·0001), with a difference between groups of -0·98 (95% CI -1·51 to -0·45; p<0·0001, adjusted for proportion of time on any disease-modifying therapy) across the 6-10 year follow-up period. INTERPRETATION: High-efficacy therapy commenced within 2 years of disease onset is associated with less disability after 6-10 years than when commenced later in the disease course. This finding can inform decisions regarding optimal sequence and timing of multiple sclerosis therapy. FUNDING: National Health and Medical Research Council Australia and MS Society UK.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020. PMID: 32199096. doi:10.1016/S1474-4422(20)30067-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。